尿路 ангиотензиноген与心力衰竭患者的死亡率与减少喷射分数之间的关系
Özcan Örsçelik1, Emrah Yeşil1, Hakan Uyar2
1Department of Cardiology, Faculty of Medicine, Mersin University, Mersin, Turkey.
Anatolian journal of cardiology
|June 8, 2023
概括
尿动血管激素水平升高表明局部氨酸-血管激素-阿尔多斯特系统激活,并与心力衰竭中死亡风险增加有关,患者的排泄分数减少.
科学领域:
- 心脏病学 心脏病学
- 脏生理学 脏生理学
- 生物标志物发现发现
背景情况:
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 在心力衰竭中起着关键作用.
- 当地RAAS对HFrEF病理生理学的影响尚未完全理解.
- 尿动血管酶原是局部RAAS激活的指标.
研究的目的:
- 调查尿动血管酶原水平与HFrEF患者全因死亡率之间的关联.
- 为了评估尿动血管酶原素作为HFrEF的预后生物标志物.
主要方法:
- 对60名HFrEF患者进行了回顾性单中心研究.
- 尿动血管增生素标准化为尿动肌.
- 患者根据尿路中位数血管新生素/肌素比率被分为两组.
- 收集了4年死亡率数据.
主要成果:
- 尿动动脉新生素/肌素比率高于中位数的组具有显著更高的全因死亡率 (71%对35.5%,P=.005).
- 尿动血管激素水平较高与死亡风险增加有关.
结论:
- 尿动血管酶原可以作为一种新的生物标志物,用于预测HFrEF患者的预后和指导随访.
- 这一发现突显了HFrEF中局部RAAS激活的临床相关性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
Heart Failure VI: Adjunct Therapies
17
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
17
Heart Failure Drugs: Diuretics
428
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
428
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
703
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
703


